6/4/2012 11:18:22 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today reported phase 1 and phase 1/2 preliminary results from three studies evaluating the safety, tolerability, dosing and response of MLN9708, the first oral proteasome inhibitor in clinical trials. The studies evaluated once or twice weekly oral dosing of MLN9708, alone or in combination, in patients with relapsed and/or refractory or previously untreated multiple myeloma (MM). These data were announced during the annual meeting of the American Society of Clinical Oncology (ASCO), held June 1-5 in Chicago, Illinois.
comments powered by